News roundup Tuesday, May 7

The latest from BioStock

» Dementia increases as we get older – AlzeCure Pharma is working on a solution
» Spago's CEO: Advancing the tumor program comes first
» EndoDrill is seen as promising new EUS technology
» This is how AlzeCure Pharma wants to take care of dementia in an aging population
» Alzinova's outgoing CEO comments on the company's potential

Read BioStock's weekly newsletter for v.18 here.

News from the last 24 hours

reports progress in pipeline and other activities. Read more.

Annexin Pharmaceuticals publishes a prospectus in connection with an upcoming rights issue. Read more.

Hamlet Biopharma has completed the first part of a controlled clinical study in patients with bladder pain. Read more.

Two international companies begin due diligence of Redwood Pharma product RP501 ahead of potential commercial agreements. Read more.

Fluicell receives Notice of Allowance from the US Patent Office for patents relating to the platform Nexocyte. Read more.

Moberg Pharma announces that MOB-015 has been approved for the treatment of mild to moderately severe nail fungus in adults in 13 EU countries. Read more.

Oncopeptides announces the final outcome of the fully guaranteed rights issue. Read more.

Ziccums vd Ann Gidner has participated in an analyst interview. Read more.

Miris Holding announces that UK Healthcare is investing in Miri's HMA to Kentucky Children's Hospital. Read more.

ADDvise Group is planning a listing change to Nasdaq Stockholm's main list. Read more.

Navamedic announces that the first treatment for erectile dysfunction without a prescription is launched in Swedish pharmacies. Read more.

Brain+ announces a partially secured rights issue of units of approximately DKK 8,94 million. Read more.

InDex Pharmaceuticals provides a status update and informs about the extraordinary general meeting on June 10. Read more.

Redwood Pharma board member describes the market situation and the commercial potential for RP501 in a video interview. Read moreThe company also announces that the company's board of directors is subscribing for units in the ongoing new share issue. Read more.

Nanoform Finland announces that nano-shaped formulation of high-concentration biologics for subcutaneous delivery will be presented by Takeda at the DDF Summit. Read more.

Gubra raises its financial outlook for 2024. Read more.

Miris Holding extends the subscription period for the company's ongoing rights issue further, to May 10. Read more.

Ascelia Pharma has published an update to investors. Read more.

Coloplast strengthens the portfolio within ostomy care with three product launches. Read more.

Change in Orions Group Management from May 31, 2025. Read more.

Photocure announces long-term benefits in bladder cancer with blue light cystoscopy and improved detection with HD technology presented at AUA 2024. Read more.

BICO Group has decided on a changed method for impairment testing of goodwill. Read more.

2cureX has decided to apply for delisting. Read more.

Novo Nordisk informs about its share buyback program. Read more.

ScandiDos The new share issue is now registered. Read more.

Duearity postpones the date of the company's annual general meeting. Read more.